Next 60 Small-Cap Biotech

Components Performance/Risk
Period Return
83.4%
Return Rank
Strong
Risk Exposure
High Risk

The selection of Biotechnology Next 60 Small-Cap Biotech firms (under $2bn) is traded mainly on the NASDAQ and, in a few instances, on the NYSE stock exchange

The companion themes of Next 60 Small-Cap Biotech are the 30 Biotech LargeCap Firms  and the Next 60 MidCap Biotech Firms

The top 100 Biotech Firms by market cap are also listed

 

Momentum highlights the trend of the average price computed over a week, compared to the monthly price average, and is indicative of the sector's resilience

Share performances can be ranked by selected time frame, from 2 weeks to one year (default), by selection  in the top-right menu

View the Analytics for fundamental ratio details 

 

The iShares Biotechnology ETF - - composed of an extensive list of more than 250 biotechnology and pharmaceutical equities, is the benchmark of this motif

The biotech selection of the Next 60 by market cap is not weighted - assuming one share of each component had been invested at the beginning of the selected period

 

Actual performance of , the tracker fund, maybe higher or lower, depending on the weighting and selection decided by the provider

Check the information available on the iShares Biotechnology ETF site or contact your advisor

Theme Components
Name
Ticker
Sector
Industry
Cur. Price
Mkt. Cap
Performance
Momentum
Risk Rank
Risk Contrib
 
Geron GERN Health CareDrug Manufacturers - Diversified1.21775 M-21.9% Sharp Down High Risk
MannKind MNKD Health CareDiabetes3.521.1 B-11.8% Strong Up High Risk
Novavax NVAX Health CareClinical trial work10.191.7 B57.0% Strong Up High Risk
Theravance Biopharma TBPH Health CareClinical trial work16.37843 M53.4% Neutral Above Average
Savara SVRA Health CareClinical trial work5.301.1 B132.5% Neutral High Risk
UroGen Pharma URGN Health CareClinical trial work27.601.3 B100.1% Neutral High Risk
Solid Biosciences SLDB Health CareClinical trial work7.24712 M49.1% Neutral High Risk
MeiraGTx Holdings MGTX Health CareClinical trial work9.57779 M48.6% Neutral High Risk
KalVista Pharmaceuticals KALV Health CareClinical trial work26.951.4 B130.3% Strong Up High Risk
Phathom Pharmaceuticals PHAT Health CareClinical trial work9.86777 M1.0% Sharp Down High Risk
1 – 10 of 60